Psilocybin & Neuropsychiatric Lyme Case Study
International Medical Case Reports Journal (Kinderlehrer D.) 3.3.23, published “The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.” The report illustrates the case of an immunocompetent male patient with serologically positive neuropsychiatric Lyme disease who had not been tolerating antimicrobial or psychotropic treatments.
After the patient started taking psilocybin in microdosed or sub-hallucinogenic amounts, his symptoms subsided. A literature analysis of the therapeutic benefits of psilocybin shows that it is both serotonergic and anti-inflammatory and thus might provide considerable therapeutic benefits to patients who are experiencing mental illness that is secondary to autoimmune inflammation.
Further study is needed regarding the use of microdosed psilocybin to treat neuropsychiatric Lyme disease and autoimmune encephalopathies.
For more information:
Read the study in International Medical Case Reports Journal.
Read more about ongoing research regarding psilocybin and Lyme disease.